近期生物医药板块表现一般，系多重因素叠加：1）行业缺乏大BD （Business Development，商务拓展）催化，在与其他热点板块的竞争中暂落下风；2）特朗普政府考虑对中国创新药采取审查等措施阴影犹在；3）港股部分明星公司出现管理层减持情况，叠加部分个股非基本面因素的暴涨暴跌。

Yin said that during the 14th Five-Year Plan period (2021-2025), China's sci-tech innovation and industrial innovation have been increasingly integrated, leading to the rapid development of new ...

NANJING, Sept. 18 (Xinhua) -- An executive of the European Union (EU) Chamber of Commerce in China called China a "golden market," as the country's ability to maintain stable growth makes it ideal for ...

It is expected that by 2026, a regular vehicle-network interaction application aimed at ordinary new energy vehicle consumers ...

[Nokia Announces Leadership Restructuring and Establishment of Two New Institutions for Technology & AI and Corporate Development] Nokia has announced the establishment of institutions for technology ...

Li, who is also a member of the Standing Committee of the Political Bureau of the Communist Party of China Central Committee, made the remarks during an inspection tour of northwest China's Gansu and ...